The Latest Breaking News on Pharma

Pfizer and its German partner BioNTech said their COVID-19 vaccine booster, adapted for the BA.4 and the BA.5 subvariants of Omicron, generated a strong immune response and was well-tolerated in testing on humans. With the results, which the companies described as consistent with preclinical data, the partners are following up…

A recent acquisition could pair nicely with the commercial infrastructure being built for the recently-approved Opzelura.

This week U.S.

Moderna stock is sharply off its highs, but the charts are showing constructive action and investors wonder whether the stock has bottomed.

Ginkgo's recent focus on drug development programs will avoid certain manufacturing risks. It also may hurt the stock's valuation.

Relmada stock crashed Thursday after its depression treatment failed a final-phase test, helping bolster rival Axsome. AXSM stock surged.

Drug wholesalers also reported depleted stocks

There are 3,439 confirmed monkeypox cases in the UK according to data for September 16

New Delhi is "seriously investigating" the deaths of 69 children in Gambia in the wake of a report that provisionally linked the fatalities to Indian-made products, the South Asian nation's foreign minister told his Gambian counterpart on Thursday.